We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Ipilimumab, Mdx010-28 | Completed Studies
Previous Study | Return to List | Next Study

Long-term Data Collection for Subjects in MDX-010 Studies (MDX010-28)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00928031
Recruitment Status : Completed
First Posted : June 25, 2009
Last Update Posted : April 26, 2010
Information provided by:
Bristol-Myers Squibb

Brief Summary:
The objective of this study is to collect disease status and overall survival information for all Subjects in MDX-010 studies.

Condition or disease
Metastatic Melanoma

Detailed Description:
This is a multicenter, follow-up study in up to 191 subjects with metastatic melanoma who were previously enrolled and treated in ipilimumab studies MDX010-02, MDX010-08, and MDX010-15. The purpose of this study is to 1) collect the date and cause of death, if known, for all deceased subjects who participated in any of the specified studies; 2) collect the date of progression for subjects who completed the studies with stable disease or better; and 3) prospectively follow all surviving subjects to determine progression-free and overall survival.

Layout table for study information
Study Type : Observational
Actual Enrollment : 160 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Collection of Long-Term Outcome Data for Subjects Who Have Previously Participated in Selected Ipilimumab (MDX-010) Studies in Metastatic Melanoma
Study Start Date : June 2007
Actual Primary Completion Date : April 2009
Actual Study Completion Date : April 2009

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects who received any dose of ipilimumab (MDX-010) in MDX010-02, MDX010-08, and MDX010-15 and were alive at the time of study completion.

Inclusion Criteria:

  1. Subjects who were previously enrolled in MDX-010 studies MDX010-02, MDX010-08, or MDX010-15.
  2. Subjects (or if applicable, next of kin), who are alive at the time of contact must have read, understood, and provided written informed consent and health Insurance Portability and Accountability Act (HIPAA) authorization after the nature of the study has been fully explained.
  3. For subjects who have died or have been lost to follow-up(the subject status at end of original ipilimumab study), approval from the appropriate site IRB, specifying or limiting appropriate means for obtaining information, must be granted prior to collection of any information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00928031

Layout table for location information
United States, Arizona
Arizona Cancer Center
Tuscon, Arizona, United States, 85724
United States, California
Pacific Shores Medical Group
Long Beach, California, United States, 90813
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
USC Norris Cancer Center
Los Angeles, California, United States, 90033
United States, Florida
University of Miami Sylvester Cancer Center
Miami, Florida, United States, 33136
United States, Indiana
St. Francis Research Foundation
Beech Grove, Indiana, United States, 46107
United States, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02115
United States, New York
NYU Cancer Institute
New York, New York, United States, 10016
United States, North Carolina
Carolinas Cancer Care
Charlotte, North Carolina, United States, 28211
United States, Oregon
Providence Portland Medical Center
Portland, Oregon, United States, 97213
United States, Utah
Huntsman Cancer Institute
Salt Lake City, Utah, United States, 84112
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for investigator information
Principal Investigator: Walter Urba, MD PhD Providence Health & Services
Layout table for additonal information
Responsible Party: Study Director, Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00928031    
Other Study ID Numbers: MDX010-28
First Posted: June 25, 2009    Key Record Dates
Last Update Posted: April 26, 2010
Last Verified: April 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas